glycemic

By Targets:	Biochemical Assay Reagents (1) Dipeptidyl Peptidase (2) Endogenous Metabolite (2) GCGR (3) GLP Receptor (1) Isotope-Labeled Compounds (1) PPAR (2)
By Research Areas:	Cardiovascular Disease (2) Inflammation/Immunology (1) Metabolic Disease (11)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15408A

Trelagliptin succinate SYR-472 succinate	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-P3463

Beinaglutide GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-113075

1,5-Anhydrosorbitol

Endogenous Metabolite Metabolic Disease

1,5-Anhydrosorbitol is a short-term marker for glycemic control.
HY-105074

Farglitazar

GI262570; GI262570X
PPAR Metabolic Disease

Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.

1,5-Anhydrosorbitol	Endogenous Metabolite	Metabolic Disease
1,5-Anhydrosorbitol is a short-term marker for glycemic control.

Farglitazar GI262570; GI262570X	PPAR	Metabolic Disease
Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-113075S

1,5-Anhydrosorbitol-13C	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
1,5-Anhydrosorbitol- ¹³C is the ¹³C labeled 1,5-Anhydrosorbitol. 1,5-Anhydrosorbitol is a short-term marker for glycemic cont[1][2].

HY-N9911

1,5-Anhydro-D-mannitol	Others	Metabolic Disease
1,5-Anhydro-D-mannitol is the analogue of 1,5-Anhydrosorbitol (HY-113075), and can be used as an experimental control. 1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-135195

Boc5	GLP Receptor	Metabolic Disease
Boc5 is a non-peptidic glucagon-like peptide-1 receptor agonist. Boc5 causes sustained glycemic control and weight loss in diabetic mice. Boc5 can be used in research of diabetic .

HY-15408

Trelagliptin SYR-472	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-P3101

GLP-1(28-36)amide	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects .

HY-P3101A

GLP-1(28-36)amide TFA	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects .

HY-100546

GSK-LSD1
GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .

HY-113058

3-Hydroxyoctanoic acid	Biochemical Assay Reagents	Others
3-Hydroxyoctanoic acid is a hydroxylated fatty acid that has been found in the LPS of Pseudomonas aeruginosa and in methyl-branched poly(3-hydroxyalkanoate) (PHA) polymers produced by Pseudomonas oleophores. It is an agonist of the orphan receptor GPR109B, increasing intracellular calcium in human neutrophils endogenously expressing GPR109B. 3-Hydroxycaprylic acid prevents lipolysis in human adipocytes and is upregulated in human plasma in response to a ketogenic diet. Plasma levels of 3-hydroxyoctanoic acid were also increased 3.41-fold in human male runners exhausted on a treadmill and in a mouse model of autism spectrum disorder (ASD) fed a high-glycemic diet.

Cat. No.	Product Name	Type

HY-113058

3-Hydroxyoctanoic acid	Biochemical Assay Reagents
3-Hydroxyoctanoic acid is a hydroxylated fatty acid that has been found in the LPS of Pseudomonas aeruginosa and in methyl-branched poly(3-hydroxyalkanoate) (PHA) polymers produced by Pseudomonas oleophores. It is an agonist of the orphan receptor GPR109B, increasing intracellular calcium in human neutrophils endogenously expressing GPR109B. 3-Hydroxycaprylic acid prevents lipolysis in human adipocytes and is upregulated in human plasma in response to a ketogenic diet. Plasma levels of 3-hydroxyoctanoic acid were also increased 3.41-fold in human male runners exhausted on a treadmill and in a mouse model of autism spectrum disorder (ASD) fed a high-glycemic diet.

3-Hydroxyoctanoic acid

Biochemical Assay Reagents

3-Hydroxyoctanoic acid is a hydroxylated fatty acid that has been found in the LPS of Pseudomonas aeruginosa and in methyl-branched poly(3-hydroxyalkanoate) (PHA) polymers produced by Pseudomonas oleophores. It is an agonist of the orphan receptor GPR109B, increasing intracellular calcium in human neutrophils endogenously expressing GPR109B. 3-Hydroxycaprylic acid prevents lipolysis in human adipocytes and is upregulated in human plasma in response to a ketogenic diet. Plasma levels of 3-hydroxyoctanoic acid were also increased 3.41-fold in human male runners exhausted on a treadmill and in a mouse model of autism spectrum disorder (ASD) fed a high-glycemic diet.

Cat. No.	Product Name	Target	Research Area

HY-P3463

Beinaglutide GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-P3101

GLP-1(28-36)amide	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects .

HY-P3101A

GLP-1(28-36)amide TFA	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113075

1,5-Anhydrosorbitol	Immune System Disorder Classification of Application Fields Source classification Disease markers Metabolic Disease Endocrine diseases Endogenous metabolite Disease Research Fields Saccharides	Endogenous Metabolite
1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-N9911

1,5-Anhydro-D-mannitol	Structural Classification Natural Products Styrax obassia Siebold & Zucc. Source classification Styracaceae Plants	Others
1,5-Anhydro-D-mannitol is the analogue of 1,5-Anhydrosorbitol (HY-113075), and can be used as an experimental control. 1,5-Anhydrosorbitol is a short-term marker for glycemic control.

Cat. No.	Product Name	Chemical Structure

HY-113075S

1,5-Anhydrosorbitol-13C

1,5-Anhydrosorbitol- ¹³C is the ¹³C labeled 1,5-Anhydrosorbitol. 1,5-Anhydrosorbitol is a short-term marker for glycemic cont[1][2].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.

glycemic

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products